Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TALS Stock Summary
In the News
3 Hot Penny Stocks to Watch Before Next Week
Navigating the world of penny stocks can often feel like a dance, full of rhythm, calculated movements, and unexpected twists. One of the popular styles in this domain is swing trading, a strategy where investors profit from the ‘swing' or fluctuations in stock prices over a short period.
Talaris (TALS) Down on Patient Death From Renal Transplant Study
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.
Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial
Shares of Talaris Therapeutics Inc. TALS, -1.63% tumbled 21.5% in premarket trading on Thursday after the company reported one of the participants in its Phase 3 study of living donor kidney transplant recipients died. The patient had been diagnosed with a moderate form of acute graft-vs-host disease.
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and livestreamed globally. In addition, members from the management team will also be in attendance.
Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on Wednesday, September 28, 2022 at 1:00 PM ET.
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences:
Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Shares of cell therapy concern Talaris Therapeutics crashed nearly 70% after GvHD outcomes in three Phase 3 trial kidney transplant patients were revealed at the end of June 2022. Even though its stock has essentially doubled off its update-induced low, it still trades at a discount to cash.
Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 AM ET at the Marriott Marquis in New York, NY.
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.
TALS Financial details
TALS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | |
Net income per share | -28.09 | -34 | -16.53 | -16.66 | |
Operating cash flow per share | -27.67 | -28.74 | -13.73 | -14.75 | |
Free cash flow per share | -28.55 | -30.66 | -14.57 | -15.49 | |
Cash per share | 61.06 | 223.61 | 83.76 | 43.95 | |
Book value per share | -26.79 | 221.4 | 83.36 | 43.65 | |
Tangible book value per share | -26.79 | 221.4 | 83.36 | 43.65 | |
Share holders equity per share | -26.79 | 221.4 | 83.36 | 43.65 | |
Interest debt per share | 0 | 0 | -0.11 | 1.33 | |
Market cap | 10.37M | 10.86M | 44.53M | 4.21M | |
Enterprise value | -28.61M | -6.73M | 25.92M | -6.58M | |
P/E ratio | -0.58 | -0.48 | -0.92 | -0.06 | |
Price to sales ratio | 0 | 0 | 0 | 0 | |
POCF ratio | -0.59 | -0.57 | -1.11 | -0.07 | |
PFCF ratio | -0.57 | -0.53 | -1.05 | -0.07 | |
P/B Ratio | -0.61 | 0.07 | 0.18 | 0.02 | |
PTB ratio | -0.61 | 0.07 | 0.18 | 0.02 | |
EV to sales | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 1.59 | 0.3 | -0.55 | 0.09 | |
EV to operating cash flow | 1.62 | 0.35 | -0.65 | 0.11 | |
EV to free cash flow | 1.57 | 0.33 | -0.61 | 0.1 | |
Earnings yield | -1.73 | -2.09 | -1.08 | -16.34 | |
Free cash flow yield | -1.76 | -1.89 | -0.95 | -15.19 | |
Debt to equity | 0 | 0 | 0 | 0.02 | |
Debt to assets | 0 | 0 | 0 | 0.01 | |
Net debt to EBITDA | 2.17 | 0.79 | 0.4 | 0.15 | |
Current ratio | 17.81 | 44.29 | 30.86 | 16.19 | |
Interest coverage | 0 | 0 | 145.73 | -29.61 | |
Income quality | 0.97 | 0.85 | 0.84 | 0.82 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0.07 | 0.06 | 0.05 | |
Capex to revenue | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.48 | -2.88 | -3.91 | -1.41 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | |
Graham number | 130.13 | 411.55 | 176.11 | 127.92 | |
ROIC | 1.06 | -0.15 | -0.2 | -0.38 | |
Return on tangible assets | -0.43 | -0.15 | -0.19 | -0.35 | |
Graham Net | -31.44 | 217.5 | 80.81 | 40.64 | |
Working capital | 38.5M | 147.35M | 238.53M | 174.15M | |
Tangible asset value | -17.1M | 148.01M | 242.81M | 180.06M | |
Net current asset value | -18.25M | 145.98M | 237.9M | 171.95M | |
Invested capital | 0 | 0 | 0 | 0.02 | |
Average receivables | 0 | 187K | 187K | 0 | |
Average payables | 0 | 717K | 1.66M | 3.22M | |
Average inventory | 0 | 406.5K | 406.5K | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | 1.05 | -0.15 | -0.2 | -0.38 | |
Capex per share | -0.88 | -1.92 | -0.84 | -0.74 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -4.4 | -3.61 | -5 | -3.49 | -1.64 | |
Operating cash flow per share | -3.25 | -3.34 | -4.04 | -3.48 | -1.64 | |
Free cash flow per share | -3.33 | -3.4 | -4.12 | -3.53 | -1.64 | |
Cash per share | 46.86 | 43.63 | 39.67 | 36.1 | 34.42 | |
Book value per share | 47.1 | 43.34 | 38.69 | 35.2 | 33.44 | |
Tangible book value per share | 47.1 | 43.34 | 38.69 | 35.2 | 33.44 | |
Share holders equity per share | 47.1 | 43.34 | 38.69 | 35.2 | 33.44 | |
Interest debt per share | 0.95 | 1.12 | -0.07 | 0.66 | 0.6 | |
Market cap | 10.88M | 4.24M | 7.86M | 12.82M | 12M | |
Enterprise value | -4.48M | -6.55M | -15.09M | -4.5M | -54.44M | |
P/E ratio | -0.15 | -0.07 | -0.09 | -0.22 | -0.43 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.81 | -0.31 | -0.46 | -0.87 | -1.71 | |
PFCF ratio | -0.79 | -0.3 | -0.46 | -0.86 | -1.71 | |
P/B Ratio | 0.06 | 0.02 | 0.05 | 0.09 | 0.08 | |
PTB ratio | 0.06 | 0.02 | 0.05 | 0.09 | 0.08 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.23 | 0.34 | 1.04 | 1.3 | 6.1 | |
EV to operating cash flow | 0.33 | 0.47 | 0.89 | 0.31 | 7.76 | |
EV to free cash flow | 0.33 | 0.46 | 0.88 | 0.3 | 7.76 | |
Earnings yield | -1.67 | -3.54 | -2.66 | -1.15 | -0.58 | |
Free cash flow yield | -1.27 | -3.34 | -2.19 | -1.16 | -0.58 | |
Debt to equity | 0.02 | 0.02 | 0.01 | 0.01 | 0 | |
Debt to assets | 0.02 | 0.01 | 0.01 | 0.01 | 0 | |
Net debt to EBITDA | 0.8 | 0.56 | 1.59 | 5 | 7.44 | |
Current ratio | 21.61 | 16.19 | 16.59 | 15.41 | 18.64 | |
Interest coverage | -24.41 | -11.19 | 15.23 | -9.35 | -4.66 | |
Income quality | 0.71 | 0.75 | 0.75 | 1 | 1 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0.02 | 0.02 | 0.02 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.6 | -0.49 | -0.5 | -0.85 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 68.27 | 59.31 | 66.01 | 52.61 | 35.15 | |
ROIC | -0.09 | -0.09 | -0.14 | -0.14 | -0.06 | |
Return on tangible assets | -0.09 | -0.08 | -0.12 | -0.09 | -0.05 | |
Graham Net | 44.03 | 40.35 | 37.07 | 33.57 | 32.5 | |
Working capital | 188.96M | 174.15M | 158.68M | 146.07M | 142.94M | |
Tangible asset value | 194.87M | 180.06M | 161.73M | 148.43M | 142.87M | |
Net current asset value | 186.45M | 171.95M | 157.98M | 145.52M | 142.86M | |
Invested capital | 0.02 | 0.02 | 0.01 | 0.01 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 2.1M | 3.01M | 3.64M | 3.16M | 1.54M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.09 | -0.08 | -0.13 | -0.1 | -0.05 | |
Capex per share | -0.08 | -0.06 | -0.08 | -0.05 | 0 |
TALS Frequently Asked Questions
What is Talaris Therapeutics, Inc. stock symbol ?
Talaris Therapeutics, Inc. is a US stock , located in Louisville of Ky and trading under the symbol TALS
What is Talaris Therapeutics, Inc. stock quote today ?
Talaris Therapeutics, Inc. stock price is $2.72 today.
Is Talaris Therapeutics, Inc. stock public?
Yes, Talaris Therapeutics, Inc. is a publicly traded company.